Skip to main content
SpringerLink
Log in

Antiplatelet, Anticoagulant, and Thrombolytic Drug Interactions

  • Protocol
Anticoagulants, Antiplatelets, and Thrombolytics

Part of the book series: Methods In Molecular Medicine™ ((MIMM,volume 93))

  • 539 Accesses

Abstract

Despite recent major pharmacological and device advances, percutaneous coronary intervention (PCI) remains a costly procedure with significant periprocedural risk. Heparin has maintained the foundation of procedural anticoagulation, but heparin anticoagulation is unpredictable because it is an indirect thrombin inhibitor, which requires heparin cofactor II-antithrombin for its actions. Antithrombin levels vary widely in patients. In addition, the heparin-antithrombin complex is too large to inhibit clot-bound or fibrin-bound thrombin. Clinical functions can alter antithrombin levels, which further reduce heparin’s predictability. Heparin can also be inhibited by plasma proteins. These complexities can lead to both excessive anticoagulation with clinical bleeding and subtherapeutic heparinization with clinical coronary occlusion. Finally, heparin is associated with a 1–3% incidence of heparin-induced thrombocytopenia (HIT), which carries an increased risk for acute, subacute, and chronic thrombotic occlusion. The major pharmacological improvement in platelet efficacy has been the addition of glycoprotein IIb/IIIa inhibitors for PCIs. However, all GPIIb/IIIa inhibitors are associated with a risk of bleeding. Reduction of heparin doses has resulted in less clinical bleeding, but bleeding still occurs in a significant number of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fitzgerald, D. and Murphy, N. (1996) Argatroban: a synthetic thrombin inhibitor of low relative molecular mass. Coron. Artery Dis. 7, 455–458.

    Article  PubMed  CAS  Google Scholar 

  2. Lewis, B., Matthas, W., Grassman, J. D., et al. (1997) Results of phase 2/3 trial of argatroban anticoagulation during PTCA of patients with heparin-induced thrombocytopenia (HIT). Circulation 96, 1–217 (abstract).

    Google Scholar 

  3. Lewis, B. E., Wallis, D. E., Berkowitz, S. D., et al. (2001) Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103, 1838–1843.

    PubMed  CAS  Google Scholar 

  4. Coussement, P. K., Bassand, J. P., Convens, C., et al. (2001) A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur. Heart J. 22, 1716–1724.

    Article  PubMed  CAS  Google Scholar 

  5. Topol, E. (1998) Toward a new frontier in myocardial reperfusion therapy: emerging platelet pre-eminence. Circulation 97, 221–218.

    Google Scholar 

  6. Coller, B. S. (1990) Platelet and thrombolytic therapy. N. Engl. J. Med. 322, 33–42.

    Article  PubMed  CAS  Google Scholar 

  7. Gold, H., Coller, B., Yasuda, T., et al. (1988) Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 77, 670–677.

    Article  PubMed  CAS  Google Scholar 

  8. Gold, H., Keriakes, D., Dinsmore, R., et al. (1997) A randomized, placebo-controlled crossover trial of ReoPro alone or combined with low dose plasminogen activator for coronary reperfusion in patients with acute myocardial infarction: preliminary results. Circulation 96, 1–474.

    Google Scholar 

  9. Antman, E., Giugliano, R., Bibson, M., et al. (1999) Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation 99, 2720–2732.

    PubMed  CAS  Google Scholar 

  10. Iqbal, O., Messmore, H., Hoppensteadt, D., Fareed, J., and Wehrmacher, W. (2000) Thrombolytic drugs in acute myocardial infarction. Clin. Applied Thromb./Haemost. 6(1), 1–13.

    Article  CAS  Google Scholar 

  11. Iqbal, O., Walenga, J. M., Lewis, B. E., and Bakhos, M. (2000) Bleeding complications with glycoprotein IIb/IIIa inhibitors. Drugs Today 36(8), 503–514.

    PubMed  CAS  Google Scholar 

  12. Turpie, G. (2000) The PENTATHLON 2000 study: comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism (VTE) after elective hip replacement surgery. Blood 96(11), Abstract #2112.

    Google Scholar 

  13. Lassen, M. R. (2000) The EPHESUS study: comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin (LMWH). The prevention of venous thromboembolism (VTE) after elective hip replacement surgery. Blood 96(11), Abstract #2109.

    Google Scholar 

  14. Erickson, B. (2000) The PENTHIFRA study: comparison of the first synthetic Factor Xa inhibitor with low molecular weight heparin (LMWH). The prevention of venous thromboembolism (VTE) after hip fracture surgery. Blood 96(11), Abstract #2110.

    Google Scholar 

  15. Bauer, K. (2000) The PENTAMAKS study: comparison of the first synthetic Factor Xa inhibitor with low molecular weight heparin. The prevention of venous thromboembolism (VTE) after elective major knee surgery. Blood 96(11), Abstract #2111.

    Google Scholar 

  16. Turpie, A. G. G., Gallus, A. S., and Hoek, J. A. (2001) For the pentasaccharide investigators: a synthetic pentasaccharide for the prevention of deep vein thrombosis after total hip replacement. N. Engl. J. Med. 344(9), 619–625.

    Article  PubMed  CAS  Google Scholar 

  17. Granger, C. B. (2002) Reperfusion therapy for Acute Myocardial Infarction, in Textbook of Cardiovascular Medicine, Vol. 5, No. 2, Lippincott, Philadelphia, PA, pp. 1–14.

    Google Scholar 

  18. Topol, E. J. (2001) The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomized trial. Lancet 357, 1905–1914.

    Article  PubMed  CAS  Google Scholar 

  19. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. The assessment of safety and efficacy of a new thrombolytic regimen (ASSENT)-3 investigators. Lancet 358, 605–613.

    Google Scholar 

  20. White, H. and the HERO-2 Investigators (2001) Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomized trial. Lancet 358, 1855–1863.

    Article  PubMed  CAS  Google Scholar 

  21. Stoen, G. W., Grines, C. L., Cox, D. A., et al. (2002) Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N. Engl. J. Med. 346, 957–966.

    Article  Google Scholar 

  22. The SPEED Group (Strategies for the Patency Enhancement in the Emergency Department) (2001) Randomized trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 101, 2788–2794.

    Google Scholar 

  23. Antman, E. M., Gibson, C. M., de Lemos, J. A., et al. (2000) Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. the Thrombolysis in Myocardial Infarction (TIMI)14 Investigators. Eur. Heart J. 21, 1944–1953.

    Article  PubMed  CAS  Google Scholar 

  24. Antman, E. M., Louwerenburg, H. W., Baars, H. F., et al. (2002) Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 105, 1642–1649.

    Article  PubMed  CAS  Google Scholar 

  25. Giugliano, R. P., Roe, M. T., Zeymer, U., et al. (2001) Restoration of epicardial and myocardial perfusion in acute ST-elevation myocardial infarction with combination eptifibatide and reduced dose tenecteplase: dose finding results from the INTEGRITI Trial (abstract). Circulation 104, II–538, 2001.

    Google Scholar 

  26. Llevadot, J., Giugliano, R. P., and Antman, E. M. (2001) Bolus fibrinolytic therapy in acute myocardial infarction. JAMA 286, 442–449.

    Article  PubMed  CAS  Google Scholar 

  27. Brener, S. J., Zeymer, U., Adgey, A. A., et al. (2002) Eptifibatide and low dose tissue plasminogen activator in acute myocardial infarction: the integrelin and low dose thrombolysis in acute myocardial infarction (INTRO-AMI) Trial. J. Am. Coll. Cardiol. 39, 377–386.

    Article  PubMed  CAS  Google Scholar 

  28. Topol, E. J. and Yadav, J. S. (2000) Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 101, 570–580.

    PubMed  CAS  Google Scholar 

  29. Roe, M. T., Ohman, E. M., Maas, A. C., et al. (2001) Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. J. Am. Coll. Cardiol. 37, 9–18.

    Article  PubMed  CAS  Google Scholar 

  30. Herrmann, H. C., Moliterno, D. J., Ohman, E. M., et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. J. Am. Coll. Cardiol. 36, 1489–1496.

    Google Scholar 

  31. Ross, A. M., Molhoek, P., Lundergan, C., et al. (2001) Randomized comparison of enoxaparin, a low molecular weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion therapy (HART II). Circulation 104, 648–652.

    Article  PubMed  CAS  Google Scholar 

  32. Wallentin, L., Dellborg, D. M., Lindahl, B., Nilsson, T., Pehrsson, K., and Swahn, E. (2001) The low-molecular-weight-heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS Study. Clin. Cardiol. 24 (3 Suppl.), L112–L114.

    Google Scholar 

  33. Alonso, A, for the AMI-SK Investigators. Preliminary results of the AMI-SK trial. Am. Coll. Cardiol. 50th Scientific Session, March 2001, Orlando, Florida.

    Google Scholar 

  34. Baird, S. H., Menown, I. B. A., McBride, S. J., Trouton, T. G., and Wilson, C. (2002) Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur. Heart J. 23, 627–632.

    Article  PubMed  CAS  Google Scholar 

  35. Direct Thrombin Inhibitor Collaboration Investigators (2002) Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patient’s data. Lancet 359, 294–302.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Loyola University Medical Center, Maywood, IL

    Omer Iqbal

  2. Albany College of Pharmacy, Albany, NY

    Shaker A. Mousa

Authors
  1. Omer Iqbal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shaker A. Mousa
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Albany College of Pharmacy, Albany, NY

    Shaker A. Mousa

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Humana Press Inc.

About this protocol

Cite this protocol

Iqbal, O., Mousa, S.A. (2004). Antiplatelet, Anticoagulant, and Thrombolytic Drug Interactions. In: Mousa, S.A. (eds) Anticoagulants, Antiplatelets, and Thrombolytics. Methods In Molecular Medicine™, vol 93. Springer, Totowa, NJ. https://doi.org/10.1385/1-59259-658-4:9

Download citation

  • DOI: https://doi.org/10.1385/1-59259-658-4:9

  • Publisher Name: Springer, Totowa, NJ

  • Print ISBN: 978-1-58829-083-0

  • Online ISBN: 978-1-59259-658-4

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation